Hinge Health (NYSE:HNGE) Director Kristina Leslie Sells 1,200 Shares of Stock

Hinge Health Inc. (NYSE:HNGE) Director Kristina Leslie sold 1,200 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $88.23, for a total value of $105,876.00. Following the sale, the director owned 30,387 shares of the company’s stock, valued at $2,681,045.01. The trade was a 3.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Hinge Health Stock Performance

NYSE HNGE opened at $88.44 on Friday. Hinge Health Inc. has a one year low of $30.08 and a one year high of $93.13. The company’s 50 day moving average price is $81.40 and its 200 day moving average price is $58.29. The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of 69.09 and a beta of 1.30.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.31. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The firm had revenue of $212.82 million for the quarter. During the same period last year, the firm earned $0.59 earnings per share. The company’s quarterly revenue was up 53.0% on a year-over-year basis. Sell-side analysts forecast that Hinge Health Inc. will post 1.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HNGE has been the subject of a number of research reports. Royal Bank Of Canada upped their price target on shares of Hinge Health from $75.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Hinge Health in a research report on Monday, August 3rd. Needham & Company LLC boosted their price objective on Hinge Health from $76.00 to $97.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $105.00 target price on Hinge Health in a research report on Wednesday, August 5th. Finally, Morgan Stanley increased their target price on Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hinge Health has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nykredit A S acquired a new stake in Hinge Health during the 2nd quarter valued at $29,000. Comprehensive Financial Management LLC acquired a new position in Hinge Health in the 2nd quarter worth $212,000. Wellington Management Group LLP boosted its position in Hinge Health by 169.7% in the 2nd quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock valued at $100,063,000 after buying an additional 758,594 shares during the last quarter. 11.2 Capital Management LLC purchased a new position in Hinge Health in the 2nd quarter valued at about $204,566,531,000. Finally, Summit Creek Advisors LLC acquired a new stake in shares of Hinge Health during the second quarter valued at about $4,972,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.